1, About LGD-4033
LGD-4033 is a selective androgen receptor modulator (SARMS), and a novel non-stero oral SARM that binds to AR with high affinity (Ki of ~1 nM) and selectivity. It is developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss.
LGD-4033 will shine more-so if ran in conjunction with SARMS S-4 and Cardarine (GW-501516). This would be similar to a SARMS triple stack that is normally ran with Ostarine, except there is a possibility of more size being put on while cutting.
A good dose for this method would be 3-5 mg a day for 8 weeks.
3, Related products we supply
Ostarine,MK-2866, Enobosarm Enobosarm (Ostarine, MK-2866, GTx-024) - affects both muscle and bone, intended mainly for osteoporosis but also general treatment for andropause and reversing muscle sarcopenia in the elderly and for cachexia in cancer patients.
LGD-4033 pharmacological profile similar to that of enobosarm, Ostarine,MK-2866
Andarine (S-4) partial agonist, intended mainly for treatment of benign prostatic hypertrophy
GW-501516 It had been investigated as a potential treatment for obesity, diabetes, dyslipidemia and cardiovascular disease
AICAR AICAR acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown
4.What is LGD-4033?
LGD-4033 is a selective androgen receptor modulator (SARMS), and a novel non-stero oral SARM that binds to AR with high affinity (Ki of ~1 nM) and selectivity. It's in a class of androgen receptor (AR) ligands that is tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. LGD-4033 is expected to produce the therapeutic benefits of test with improved safety, tolerability and patient acceptance due to tissue-selective mechanism of action and an oral route of administration.
5.How it works
LGD-4033, a novel nonstero, oral selective androgen receptor modulator, binds to the androgen receptor with high affinity and selectivity. It demonstrates anabolic activity in muscles, anti-resorptive and anabolic activity in bones and a robust selectivity for muscle and bone versus prostate and sebaceous glands. LGD-4033 has recently completed a Phase I Multiple Ascending Dose study in healthy volunteers. This randomized, double-blind, placebo-controlled Phase I study established the safety and tolerability up to doses of 22 mg per day.